MedPath

The efficacy and feasibility of the repeated intraperitoneal Paclitaxel +systemic TS-1 and Paclitaxel for far advanced or recurrent gastric cancer: Phase I/II trial.

Phase 1
Conditions
Far advanced or recurrent gastric cancer
Registration Number
JPRN-UMIN000000636
Lead Sponsor
Department of Surgical Oncology The University of Tokyo
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Sex
All
Target Recruitment
40
Inclusion Criteria

Not provided

Exclusion Criteria

Other hematogeneous metastasis multiple cancers other cases who are decided to be inappropriate for the clinical trial by doctors.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath